- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00369382
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
25 maja 2011 zaktualizowane przez: Wyeth is now a wholly owned subsidiary of Pfizer
A Randomized Open-Label Study To Compare The Safety And Efficacy Of Conversion From A Calcineurin Inhibitor To Sirolimus Vs Continued Use Of A Calcineurin Inhibitor In Heart Transplant Recipients With Mild-Moderate Impaired Renal Function
The primary purpose of this study is to determine whether converting from calcineurin inhibitor (CNI) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal function in cardiac transplant recipients with mild to moderate renal dysfunction.
Przegląd badań
Status
Zakończony
Interwencja / Leczenie
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
121
Faza
- Faza 4
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- Pfizer Investigational Site
-
-
-
-
-
Vienna, Austria, A-1090
- Pfizer Investigational Site
-
-
-
-
-
Barcelona, Hiszpania, 08036
- Pfizer Investigational Site
-
La Coru?a, Hiszpania, 15001
- Pfizer Investigational Site
-
Madrid, Hiszpania, 28035
- Pfizer Investigational Site
-
Sevilla, Hiszpania, 41013
- Pfizer Investigational Site
-
Valencia, Hiszpania, 46009
- Pfizer Investigational Site
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Hiszpania, 08907
- Pfizer Investigational Site
-
-
Cantabria
-
Santander, Cantabria, Hiszpania, 39008
- Pfizer Investigational Site
-
-
-
-
-
Quebec, Kanada, G1V 4G5
- Pfizer Investigational Site
-
-
Quebec
-
Montreal, Quebec, Kanada, H1T 1C8
- Pfizer Investigational Site
-
Sainte-Foy, Quebec, Kanada, G1V 4G5
- Pfizer Investigational Site
-
-
-
-
-
Auckland, Nowa Zelandia
- Pfizer Investigational Site
-
-
Auckland
-
Epsom, Auckland, Nowa Zelandia, 1003
- Pfizer Investigational Site
-
-
-
-
Florida
-
Tampa, Florida, Stany Zjednoczone, 33606
- Pfizer Investigational Site
-
-
Minnesota
-
Rochester, Minnesota, Stany Zjednoczone, 55905
- Pfizer Investigational Site
-
-
New York
-
New York, New York, Stany Zjednoczone, 10027-6902
- Pfizer Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
- Pfizer Investigational Site
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19102
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15213
- Pfizer Investigational Site
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77030
- Pfizer Investigational Site
-
-
Virginia
-
Norfolk, Virginia, Stany Zjednoczone, 23507
- Pfizer Investigational Site
-
-
-
-
-
Bern, Szwajcaria, 3010
- Pfizer Investigational Site
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat i starsze (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Wszystko
Opis
Inclusion Criteria:
- Cardiac transplant recipients age 18 years or older receiving cyclosporine or tacrolimus since the time of transplant.
- 12 months after cardiac transplantation but less than 96 months post-transplantation.
Exclusion Criteria:
- Multiple-organ transplant recipients (such as heart-lung, heart-kidney, or heart after kidney transplant recipients).
- Prior or current use of sirolimus or everolimus unless administration was part of a "CNI holiday" lasting no more than 10 days.
- History of acute rejection within the last 3 months, malignancy within the last 5 years (except for adequately treated basal cell or squamous cell carcinoma of the skin), and human immunodeficiency virus (HIV) patients.
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: 1
Group 1: Continuation of CNI regimen
|
Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific.
Duration should be 52 weeks on-therapy.
Inne nazwy:
|
|
Eksperymentalny: 2
Group 2: (CNI-Free) Conversion to SRL-based regimen
|
Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL.
Duration should be 52 weeks on-therapy.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at 52 Weeks Post-randomization
Ramy czasowe: Baseline and Week 52
|
Creatinine Clearance (CC) calculated using Cockcroft-Gault equation, adjusted for body surface area.
Calculated CC: method to approximate kidney function.
It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys.
Normal adult creatinine clearance is greater than or equal to (≥) 90 milliliters per minute per 1.73 meters squared (mL/min/1.73m^2).
Change from baseline=CC at Week 52 minus CC at baseline where higher scores represented improved renal function; Least squares mean adjusted for baseline calculated creatinine clearance and center.
|
Baseline and Week 52
|
|
Calculated Creatinine Clearance (Cockcroft-Gault Equation) at Baseline
Ramy czasowe: Baseline
|
Creatinine clearance at baseline calculated using Cockcroft-Gault equation and adjusted for body surface area.
Calculated CC: method to approximate kidney function.
It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys.
Normal adult creatinine clearance is ≥ 90 mL/min/1.73m^2.
|
Baseline
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at 4, 16, 24, 32, and 40 Weeks Post-randomization
Ramy czasowe: Baseline and Weeks 4, 16, 24, 32, and 40
|
Creatinine Clearance (CC) calculated using Cockcroft-Gault equation, adjusted for body surface area.
Calculated CC: method to approximate kidney function.
It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys.
Normal adult creatinine clearance is ≥ 90 mL/min/1.73m^2.
Change from baseline=CC at Week X minus CC at baseline where higher scores represented improved renal function; Least squares mean adjusted for baseline calculated creatinine clearance and center.
|
Baseline and Weeks 4, 16, 24, 32, and 40
|
|
Change From Baseline in Calculated Creatinine Clearance (Modification of Diet in Renal Disease [MDRD] Equation) at 4, 16, 24, 32, 40 and 52 Weeks Post-randomization
Ramy czasowe: Baseline and Weeks 4, 16, 24, 32, 40 and 52
|
Creatinine clearance calculated using MDRD equation.
Normal adult creatinine clearance is ≥ 90 mL/min/1.73m^2.
Change from baseline=CC at Week X minus CC at baseline where higher scores represented improved renal function.
Least squares mean adjusted for baseline calculated creatinine clearance (MDRD) and center.
|
Baseline and Weeks 4, 16, 24, 32, 40 and 52
|
|
Calculated Creatinine Clearance (Modification of Diet in Renal Disease [MDRD] Equation) at Baseline
Ramy czasowe: Baseline
|
Creatinine clearance calculated using MDRD equation.
Calculated CC: method to approximate kidney function.
It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys.
Normal adult creatinine clearance is ≥ 90 mL/min/1.73m^2.
|
Baseline
|
|
Change From Baseline in Serum Creatinine Level at 4, 16, 24, 32, 40, and 52 Weeks Post-randomization
Ramy czasowe: Baseline and Weeks 4, 16, 24, 32, 40, and 52
|
Serum creatinine is an indicator of kidney function.
Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue.
It is removed from the blood by the kidneys and excreted in urine.
Normal adult blood levels of creatinine=45 to 90 micromoles per liter (mcmol/L) for females, 60 to 110 mcmol/L for males, however normal values are age-dependent.
Change from baseline=creatinine level at Week x minus baseline level where higher scores represented decreased kidney function.
Least squares mean adjusted for treatment group and center.
|
Baseline and Weeks 4, 16, 24, 32, 40, and 52
|
|
Serum Creatinine Level at Baseline
Ramy czasowe: Baseline
|
Serum creatinine is an indicator of kidney function.
Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue.
It is removed from the blood by the kidneys and excreted in urine.
|
Baseline
|
|
Annual Change in Calculated Creatinine Clearance (Cockcroft-Gault Equation)
Ramy czasowe: Baseline to discontinuation (up to Week 52)
|
The change in creatinine clearance over time assessed using the random coefficient slope of the regression line with creatinine clearance as the dependent variable and study day as the independent variable.
Time points calculated as study days, relative to time of randomization of study medication.
Observed data multiplied by a scale factor of 365 to express an annual change.
|
Baseline to discontinuation (up to Week 52)
|
|
Overall Survival (OS)
Ramy czasowe: Baseline until death (up to Week 56)
|
Survival time from the start of study treatment to date of death due to any cause, censored at the last visit if no death.
Death was determined from the Death report.
The distribution of time to death was to be estimated using Kaplan-Meier method and compared between treatment groups with a proportional hazard model.
The number and percent of survival at 6 and 12 months were to be reported.
|
Baseline until death (up to Week 56)
|
|
Number of Participants With Acute Rejection
Ramy czasowe: Baseline to Week 52
|
Based on International Society for Heart and Lung Transplantation [ISHLT] 1990 criteria: rejections Grade 3A or higher, rejection accompanied by hemodynamic compromise or requiring treatment.
Grade 3A or higher included: multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis.
Biopsies performed for clinically suspected rejection (for cause), site's standard of care (site protocol biopsy), or protocol mandated.
|
Baseline to Week 52
|
|
Number of Participants With Biopsy-confirmed Acute Rejection by Severity
Ramy czasowe: Baseline to Week 52
|
Severity of acute rejection summarized using revised 2005 ISHLT criteria.
Grade 0R: no rejection, Grade 1R: Focal (perivascular or interstitial) infiltrate without necrosis, diffuse but sparse infiltrate without necrosis, or one focus only with aggressive infiltration and/or focal myocyte damage, Grade 2R:Multifocal aggressive infiltrates and/or myocyte damage, and Grade 3R:Diffuse inflammatory process with necrosis, or diffuse aggressive polymorphous with necrosis, increased infiltrate, changes in edema, hemorrhage and vasculitis.
|
Baseline to Week 52
|
|
Time to First Acute Rejection
Ramy czasowe: Baseline to Week 52
|
Time from baseline to first biopsy-confirmed acute rejection defined as any of the following (based on ISHLT 1990 criteria): all rejections Grade 3A or higher, any rejection accompanied by hemodynamic compromise, or any rejection requiring treatment.
ISHLT Grade 3A or higher included: Multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis.
|
Baseline to Week 52
|
|
Number of Participants Requiring Antibody Use in Treatment of Acute Rejection
Ramy czasowe: Baseline to Week 52
|
Number of participants requiring antilymphocyte antibody therapy with suspected or biopsy-proven, steroid-resistant, acute rejection with or without hemodynamic compromise.
Acute rejection based on ISHLT 1990 criteria: all rejections Grade 3A or higher, any rejection accompanied by hemodynamic compromise, or any rejection requiring treatment.
ISHLT Grade 3A or higher included: Multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis.
|
Baseline to Week 52
|
|
Number of Participants in Sirolimus Treatment Group Requiring Conversion Back to CNI Therapy
Ramy czasowe: Baseline up to Week 52
|
Baseline up to Week 52
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
1 września 2006
Zakończenie podstawowe (Rzeczywisty)
1 kwietnia 2010
Ukończenie studiów (Rzeczywisty)
1 maja 2010
Daty rejestracji na studia
Pierwszy przesłany
25 sierpnia 2006
Pierwszy przesłany, który spełnia kryteria kontroli jakości
25 sierpnia 2006
Pierwszy wysłany (Oszacować)
29 sierpnia 2006
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
30 maja 2011
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
25 maja 2011
Ostatnia weryfikacja
1 maja 2011
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby nerek
- Choroby Urologiczne
- Niewydolność nerek
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwinfekcyjne
- Inhibitory enzymów
- Środki przeciwreumatyczne
- Środki przeciwnowotworowe
- Środki immunosupresyjne
- Czynniki immunologiczne
- Środki dermatologiczne
- Środki przeciwbakteryjne
- Antybiotyki, Przeciwnowotworowe
- Środki przeciwgrzybicze
- Inhibitory kalcyneuryny
- Takrolimus
- Syrolimus
- Cyklosporyna
- Cyklosporyny
Inne numery identyfikacyjne badania
- 0468E7-408
- B1741006 (Inny identyfikator: Pfizer)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .